Did Pfizer Just Say "Checkmate" to Novo Nordisk?

The words "Ozempic" and "Wegovy" almost have become household names as these products have changed the lives of many – from our own friends and family to celebrities. These drugs, prescribed for weight loss, have been in high demand, and this has driven revenue of drugmaker Novo Nordisk (NYSE: NVO) higher over time.But in recent quarters, Novo has lost some ground to rival Eli Lilly, the maker of Mounjaro and Zepbound -- and the company also faces potential competition down the road from others. Though Novo and Lilly dominate the market today, fellow pharma companies and biotech players have set their sights on joining.And one of them is pharmaceutical giant Pfizer (NYSE: PFE). Now, with a major step along the path to entering this billion-dollar market, did Pfizer just say "checkmate" to Novo Nordisk? Let's find out.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool